Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient
T. Furuta et al., Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient, CLIN PHARM, 67(6), 2000, pp. 684-689
A 53-year old female patient with duodenal ulcer and Helicobacter pylori in
fection was treated three times with a proton pump inhibitor-based triple t
herapy, such as lansoprazole-clarithromycin-amoxicillin (INN, amoxicilline)
and lansoprazole-minocycline-cefaclor: However, the H pylori infection was
not cured. A culture test revealed that her infection was a clarithromycin
-resistant but amoxicillin-sensitive strain of H pylori. Moreover, a polyme
rase chain reaction-restriction fragment length polymorphism (PCR-RFLP) ana
lysis revealed that she was a homozygous extensive metabolizer of cytochrom
e P450 (CYP) 2C19 (wt/wt). The usual dose of the proton pump inhibitor was
therefore assumed to be insufficient for her and then she was treated with
a high dose of omeprazole (120 mg/day) and amoxicillin (2250 mg/day) for 2
weeks. The H pylori infection and the ulcer lesion were then cured. One of
the factors associated with success or failure of cure of H pylori infectio
n by the proton pump inhibitor-based triple therapy appeared to be CYP2C19
genotype status. Dual treatment with a sufficient dose of a proton pump inh
ibitor plus amoxicillin could cure H pylori infection even after the failur
e to cure H pylori infection by a usual proton pump inhibitor-based triple
therapy in patients with the wt/wt homozygous extensive metabolizer genotyp
e of CYP2C19.